HER2+ Breast Cancer | Specialty

Latest News & Insight: October 1, 2014

October 1st 2014

CLEOPATRA Trial Update Shows Dramatic OS Benefit

September 28th 2014

Dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median OS by almost 16 months over standard first-line therapy.

Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study

September 28th 2014

Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Pertuzumab Use Continues to Expand in Breast Cancer

September 17th 2014

Treatment strategies that incorporate pertuzumab (Perjeta) continue to evolve as more clinical trial data becomes available.

CDK 4/6, PI3K Inhibitor Combinations Explored in Breast Cancer

September 11th 2014

The combination of letrozole with either the CDK4/6 inhibitor LEE011 or the PI3 kinase Inhibitor BYL719 demonstrated clinical activity for women with ER-positive, HER2-negative breast cancer.

Hurvitz Discusses PIK3CA Mutations, pCR, CDK4/6 Inhibitors, and Immunotherapies in Breast Cancer

September 9th 2014

Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.

Adding Trastuzumab to Fulvestrant Prolongs Responses in Metastatic Breast Cancer

September 7th 2014

The addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with metastatic breast cancer.

Novel Peptide Vaccine Safe, Effective in High-Risk Breast Cancer

September 6th 2014

A novel HER2-derived peptide vaccine designed to stimulate CD8+ cytotoxic T-lymphocytes reduced the rate of breast cancer recurrence and proved safe and well tolerated in the adjuvant setting.

Dr. Tripathy Provides an Overview of the SystHERs Registry

September 2nd 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, provides an overview of the SystHERs registry.

Dr. O'Regan Discusses Updates in HER2-Positive Breast Cancer

August 14th 2014

Ruth M. O'Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

Favorable Safety Profile of T-DM1 Confirmed in Large Study

August 13th 2014

The favorable safety profile of T-DM1 makes it apt to be looked at in other settings of breast cancer.

Tripathy Offers Perspective on HER2-Positive Breast Cancer

August 13th 2014

The ever-evolving treatment landscape for patients with HER2-positive breast cancer leaves several questions unanswered regarding therapeutic sequences and whether an optimal standard of care exists.

Utilizing Bisphosphonates in Breast Cancer

August 7th 2014

TEXT/SOFT Findings in HR-Positive Breast Cancer

August 7th 2014

Adjuvant Everolimus and CDK4/6 Trials in Breast Cancer

August 7th 2014

Managing the Toxicity of Everolimus in Breast Cancer

August 7th 2014

Second-Line Everolimus in Metastatic Breast Cancer

August 7th 2014

Frontline Treatment of ER-Positive Breast Cancer

August 7th 2014

T-DM1 Plus Pertuzumab in the MARIANNE Trial

August 7th 2014

Fitting T-DM1 Into Established Upfront Treatment Paradigms

August 7th 2014